Shota Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shota Yamamoto has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Terumitsu Hasebe
Department of Radiology, Tokai University Hachioji Hospital, Tokai University School of Medicine, 1838 Ishikawa-machi, Hachioji , Tokyo , Japan
6 shared publications - Fumio Sakamaki
Department of Respiratory Medicine, Tokai University Hachioji Hospital, Ishikawa-machi 1838, Hachioji, Tokyo, 192-0032, Japan
5 shared publications Shunsuke Kamei
Department of Radiology Tokai University Hachioji Hospital, Tokai University School of Medicine Tokyo Japan
5 shared publicationsHaruhito Sugiyama
Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan
4 shared publicationsKonomi Kobayashi
Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan
4 shared publicationsMasayuki Hojo
Respiratory Disease Center, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan
4 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Identifying effect modifiers of corticosteroids in acute respiratory distress syndrome: a meta-regression analysis of randomized controlled trials
Systemic corticosteroids are administered in acute respiratory distress syndrome (ARDS) for their anti-inflammatory effects. However, the factors that influence their therapeutic efficacy remain poorly understood. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating corticosteroid therapy in adults with non-COVID ARDS. Comprehensive searches of PubMed, CENTRAL, and Web of Science were performed through October 2024. A random-effects model was used to pool the risk ratios (RRs) for short-term all-cause mortality. Inverse-variance-weighted univariable meta-regression analyses were conducted to assess associations between study-level characteristics and treatment effects. Subgroup analysis was performed based on the era of lung-protective ventilation (LPV) adoption using a random-effects model. Adverse events including intensive care unit (ICU)-acquired weakness, superinfection, and barotrauma were also evaluated. The credibility of subgroup effects was evaluated using Instrument for assess the Credibility of Effect Modification Analyses (ICEMAN), and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Eleven RCTs encompassing 1,441 patients met inclusion criteria. Meta-regression identified year of publication as the only potential of effect modifier (coefficient: -0.014; 95% confidence interval [CI]: -0.031 to 0.002; p = 0.082). Subgroup analysis of short-term mortality showed a lower RR in trials conducted after LPV implementation (RR 0.65; 95% CI: 0.50 to 0.86) than in earlier trials (RR 0.86; 95% CI: 0.73 to 1.02), although a between-subgroup difference was not apparent (p = 0.095). Both ICEMAN credibility of subgroup effect and GRADE certainty of evidence were moderate. A sensitivity analysis using the longest available mortality time point showed a consistent directional pattern (RR 0.71; 95% CI 0.54 to 0.94 after LPV, compared with RR 0.86; 95% CI 0.73 to 1.01 before LPV; p = 0.253). Analyses of adverse events suggested a potential increase in ICU-acquired weakness, no clear increase in superinfection, and a possible reduction in barotrauma. Benefit appears larger in more recent trials conducted in the LPV era; this may reflect improvements in ventilatory care, optimization of steroid regimens, and other secular changes in non-COVID ARDS, highlighting the need for further stratified research. PROSPERO CRD42024597366. The online version contains supplementary material available at 10.1186/s12890-026-04236-9.
- 17 March 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessIdentifying effect modifiers of corticosteroids in acute respiratory distress syndrome: a meta-regression analysis of randomized controlled trials
Systemic corticosteroids are administered in acute respiratory distress syndrome (ARDS) for their anti-inflammatory effects. However, the factors that influence their therapeutic efficacy remain poorly understood. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating corticosteroid therapy in adults with non-COVID ARDS. Comprehensive searches of PubMed, CENTRAL, and Web of Science were performed through October 2024. A random-effects model was used to pool the risk ratios (RRs) for short-term all-cause mortality. Inverse-variance-weighted univariable meta-regression analyses were conducted to assess associations between study-level characteristics and treatment effects. Subgroup analysis was performed based on the era of lung-protective ventilation (LPV) adoption using a random-effects model. Adverse events including intensive care unit (ICU)-acquired weakness, superinfection, and barotrauma were also evaluated. The credibility of subgroup effects was evaluated using Instrument for assess the Credibility of Effect Modification Analyses (ICEMAN), and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Eleven RCTs encompassing 1,441 patients met inclusion criteria. Meta-regression identified year of publication as the only potential of effect modifier (coefficient: -0.014; 95% confidence interval [CI]: -0.031 to 0.002; p = 0.082). Subgroup analysis of short-term mortality showed a lower RR in trials conducted after LPV implementation (RR 0.65; 95% CI: 0.50 to 0.86) than in earlier trials (RR 0.86; 95% CI: 0.73 to 1.02), although a between-subgroup difference was not apparent (p = 0.095). Both ICEMAN credibility of subgroup effect and GRADE certainty of evidence were moderate. A sensitivity analysis using the longest available mortality time point showed a consistent directional pattern (RR 0.71; 95% CI 0.54 to 0.94 after LPV, compared with RR 0.86; 95% CI 0.73 to 1.01 before LPV; p = 0.253). Analyses of adverse events suggested a potential increase in ICU-acquired weakness, no clear increase in superinfection, and a possible reduction in barotrauma. Benefit appears larger in more recent trials conducted in the LPV era; this may reflect improvements in ventilatory care, optimization of steroid regimens, and other secular changes in non-COVID ARDS, highlighting the need for further stratified research. PROSPERO CRD42024597366. The online version contains supplementary material available at 10.1186/s12890-026-04236-9.
- Open Access
- 21 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 911-920
Comparison of oxygenation targets in critically ill adults: a systematic review and network meta-analysis of randomized controlled trials
Ryosuke Imai, MD, MMSc, Ryohei Yamamoto, MD, PhD, Takayuki Niitsu, MD, Ann-Marcia C Tukpah, MD, MPH, MS, Ryo Kamidani, MD, PhD, Hiroki Sato, PhD, Yohei Iwa
- 21 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 911-920
Open AccessComparison of oxygenation targets in critically ill adults: a systematic review and network meta-analysis of randomized controlled trials
Ryosuke Imai, MD, MMSc, Ryohei Yamamoto, MD, PhD, Takayuki Niitsu, MD, Ann-Marcia C Tukpah, MD, MPH, MS, Ryo Kamidani, MD, PhD, Hiroki Sato, PhD, Yohei Iwa
- Open Access
- 16 February 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101389
Current perspectives on imaging modalities in the diagnosis and management of pulmonary hypertension
- 16 February 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101389
Open AccessCurrent perspectives on imaging modalities in the diagnosis and management of pulmonary hypertension
- Open Access
- 2 September 2025
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (4)
Comparison of Corticosteroid Regimens for COVID-19 and Non-COVID-19 ARDS
- 2 September 2025
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (4)
Open AccessComparison of Corticosteroid Regimens for COVID-19 and Non-COVID-19 ARDS
- 6 January 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-14
Surgical and Bronchoscopic Lung Volume Reduction for Severe Emphysema: A Systematic Review and Network Meta-analysis
Background Along with lung volume reduction surgery (LVRS), bronchoscopic lung volume reduction is a treatment option for end-stage emphysema. However, comparisons among interventions remain insufficient. Methods We searched on PubMed, CENTRAL, Embase, and Web of Science. We included randomized controlled trials with outcomes measuring mid-term mortality within 6 months, changes in forced expiratory volume in one second (FEV1), St. George’s Respiratory Questionnaire (SGRQ), six-minute walk distance (6MWD) from baseline, adverse event related to procedures, and long-term mortality within 5 years. Bayesian network meta-analysis was performed. The certainty was assessed by CINeMA. Results Twenty-five randomized controlled trials involving 4,283 patients were included, identifying seven types of procedures and standard of care. Mid-term mortality increased in LVRS and endobronchial valve (EBV) (LVRS, risk ratio [RR] 3.26, 95% CrI 1.98–6.21, low certainty; EBV, RR 2.06 95% CrI 1.07–4.36, moderate certainty). LVRS showed the largest improvements: change in FEV1 (187.2 mL, 95% CrI 166.4–209.6), 6MWD (42.2 m, 95% CrI 33.2–50.5), and SGRQ (− 13.29 points, 95% CrI − 27.25–0.75). Among bronchoscopic procedures, high efficacy was noted in EBV and endobronchial coil (EBC) for FEV1 changes (EBV, 111.8 mL, 95% CrI 92.2–136.2; EBC, 74.1 mL, 95% CrI 47.6–101.7). Pneumothorax increased in these two procedures (EBV, RR 12.75, 95% CrI 5.52–35.48; EBC, RR 4.95, 95% CrI 1.12–40.90). Conclusion LVRS offers high efficacies but is accompanied by increased mid-term mortality. EBV and EBC also showed effectiveness; however, they increased pneumothorax, and EBV slightly increased mortality. For accurate assessment, long-term survival data of BLVR are needed.
- 6 January 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-14
Surgical and Bronchoscopic Lung Volume Reduction for Severe Emphysema: A Systematic Review and Network Meta-analysis
Background Along with lung volume reduction surgery (LVRS), bronchoscopic lung volume reduction is a treatment option for end-stage emphysema. However, comparisons among interventions remain insufficient. Methods We searched on PubMed, CENTRAL, Embase, and Web of Science. We included randomized controlled trials with outcomes measuring mid-term mortality within 6 months, changes in forced expiratory volume in one second (FEV1), St. George’s Respiratory Questionnaire (SGRQ), six-minute walk distance (6MWD) from baseline, adverse event related to procedures, and long-term mortality within 5 years. Bayesian network meta-analysis was performed. The certainty was assessed by CINeMA. Results Twenty-five randomized controlled trials involving 4,283 patients were included, identifying seven types of procedures and standard of care. Mid-term mortality increased in LVRS and endobronchial valve (EBV) (LVRS, risk ratio [RR] 3.26, 95% CrI 1.98–6.21, low certainty; EBV, RR 2.06 95% CrI 1.07–4.36, moderate certainty). LVRS showed the largest improvements: change in FEV1 (187.2 mL, 95% CrI 166.4–209.6), 6MWD (42.2 m, 95% CrI 33.2–50.5), and SGRQ (− 13.29 points, 95% CrI − 27.25–0.75). Among bronchoscopic procedures, high efficacy was noted in EBV and endobronchial coil (EBC) for FEV1 changes (EBV, 111.8 mL, 95% CrI 92.2–136.2; EBC, 74.1 mL, 95% CrI 47.6–101.7). Pneumothorax increased in these two procedures (EBV, RR 12.75, 95% CrI 5.52–35.48; EBC, RR 4.95, 95% CrI 1.12–40.90). Conclusion LVRS offers high efficacies but is accompanied by increased mid-term mortality. EBV and EBC also showed effectiveness; however, they increased pneumothorax, and EBV slightly increased mortality. For accurate assessment, long-term survival data of BLVR are needed.
- 29 August 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (2) , 2400745
Sputum colour matters: haemoptysis in a bronchiectasis registry
Shareable abstract Expansion of sputum data categorisation in future bronchiectasis registries may lead to appropriate assessment of exacerbations and identification of severe phenotypeshttps://bit.ly/3JElUFh
- 29 August 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (2) , 2400745
Sputum colour matters: haemoptysis in a bronchiectasis registry
Shareable abstract Expansion of sputum data categorisation in future bronchiectasis registries may lead to appropriate assessment of exacerbations and identification of severe phenotypeshttps://bit.ly/3JElUFh
- RetractedOpen Access
- 13 September 2022
- Published by Wiley in Journal of Medical Radiation Sciences
- Vol. 70 (4) , E1-E11
Retracted: Chest digital dynamic radiography to detect changes in human pulmonary perfusion in response to alveolar hypoxia
Introduction: Hypoxic pulmonary vasoconstriction optimises oxygenation in the lung by matching the local‐blood perfusion to local‐ventilation ratio upon exposure to alveolar hypoxia. It plays an important role in various pulmonary diseases, but few imaging evaluations of this phenomenon in humans. This study aimed to determine whether chest digital dynamic radiography could detect hypoxic pulmonary vasoconstriction as changes in pulmonary blood flow in healthy individuals.Methods: Five Asian men underwent chest digital dynamic radiography before and after 60 sec breath‐holding at the maximal inspiratory level in upright and supine positions. Alveolar partial pressure of oxygen and atmospheric pressure were calculated using the blood gas test and digital dynamic radiography imaging, respectively. To evaluate the blood flow, the correlation rate of temporal change in each pixel value between the lung fields and left cardiac ventricles was analysed.Results: Sixty seconds of breath‐holding caused a mean reduction of 26.7 ± 6.4 mmHg in alveolar partial pressure of oxygen. The mean correlation rate of blood flow in the whole lung was significantly lower after than before breath‐holding (before, upright 51.5%, supine 52.2%; after, upright 45.5%, supine 46.1%; both P < 0.05). The correlation rate significantly differed before and after breath‐holding in the lower lung fields (upright, 11.8% difference; supine, 10.7% difference; both P < 0.05). The mean radiation exposure of each scan was 0.98 ± 0.09 mGy. No complications occurred.Conclusions: Chest digital dynamic radiography could detect the rapid decrease in pulmonary perfusion in response to alveolar hypoxia. It may suggest hypoxic pulmonary vasoconstriction in healthy individuals.
- 13 September 2022
- Published by Wiley in Journal of Medical Radiation Sciences
- Vol. 70 (4) , E1-E11
RetractedOpen AccessRetracted: Chest digital dynamic radiography to detect changes in human pulmonary perfusion in response to alveolar hypoxia
Introduction: Hypoxic pulmonary vasoconstriction optimises oxygenation in the lung by matching the local‐blood perfusion to local‐ventilation ratio upon exposure to alveolar hypoxia. It plays an important role in various pulmonary diseases, but few imaging evaluations of this phenomenon in humans. This study aimed to determine whether chest digital dynamic radiography could detect hypoxic pulmonary vasoconstriction as changes in pulmonary blood flow in healthy individuals.Methods: Five Asian men underwent chest digital dynamic radiography before and after 60 sec breath‐holding at the maximal inspiratory level in upright and supine positions. Alveolar partial pressure of oxygen and atmospheric pressure were calculated using the blood gas test and digital dynamic radiography imaging, respectively. To evaluate the blood flow, the correlation rate of temporal change in each pixel value between the lung fields and left cardiac ventricles was analysed.Results: Sixty seconds of breath‐holding caused a mean reduction of 26.7 ± 6.4 mmHg in alveolar partial pressure of oxygen. The mean correlation rate of blood flow in the whole lung was significantly lower after than before breath‐holding (before, upright 51.5%, supine 52.2%; after, upright 45.5%, supine 46.1%; both P < 0.05). The correlation rate significantly differed before and after breath‐holding in the lower lung fields (upright, 11.8% difference; supine, 10.7% difference; both P < 0.05). The mean radiation exposure of each scan was 0.98 ± 0.09 mGy. No complications occurred.Conclusions: Chest digital dynamic radiography could detect the rapid decrease in pulmonary perfusion in response to alveolar hypoxia. It may suggest hypoxic pulmonary vasoconstriction in healthy individuals.